DE60335099D1 - Thiadiazole oder oxadiazole und ihre verwendung als jak proteinkinaseinhibitoren - Google Patents
Thiadiazole oder oxadiazole und ihre verwendung als jak proteinkinaseinhibitorenInfo
- Publication number
- DE60335099D1 DE60335099D1 DE60335099T DE60335099T DE60335099D1 DE 60335099 D1 DE60335099 D1 DE 60335099D1 DE 60335099 T DE60335099 T DE 60335099T DE 60335099 T DE60335099 T DE 60335099T DE 60335099 D1 DE60335099 D1 DE 60335099D1
- Authority
- DE
- Germany
- Prior art keywords
- kinaseinhibitors
- thiadiazole
- oxadiazole
- jak protein
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 102000015617 Janus Kinases Human genes 0.000 abstract 1
- 108010024121 Janus Kinases Proteins 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000005787 hematologic cancer Diseases 0.000 abstract 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37818502P | 2002-05-06 | 2002-05-06 | |
PCT/US2003/014223 WO2004058753A1 (en) | 2002-05-06 | 2003-05-06 | Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60335099D1 true DE60335099D1 (de) | 2011-01-05 |
Family
ID=32681783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60335099T Expired - Lifetime DE60335099D1 (de) | 2002-05-06 | 2003-05-06 | Thiadiazole oder oxadiazole und ihre verwendung als jak proteinkinaseinhibitoren |
Country Status (14)
Country | Link |
---|---|
US (1) | US7271179B2 (de) |
EP (2) | EP1501829B1 (de) |
JP (2) | JP4681302B2 (de) |
KR (1) | KR20050006237A (de) |
CN (1) | CN1665808A (de) |
AT (1) | ATE489384T1 (de) |
AU (1) | AU2003299472A1 (de) |
CA (1) | CA2485429A1 (de) |
DE (1) | DE60335099D1 (de) |
IL (1) | IL165067A0 (de) |
MX (1) | MXPA04011048A (de) |
NO (1) | NO20045282L (de) |
RU (1) | RU2004135386A (de) |
WO (1) | WO2004058753A1 (de) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103169708B (zh) | 2002-07-29 | 2018-02-02 | 里格尔药品股份有限公司 | 用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法 |
DE102004009933A1 (de) * | 2004-02-26 | 2005-09-15 | Merck Patent Gmbh | Verwendung von Thiadiazolharnstoffderivaten |
US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
KR20070032648A (ko) * | 2004-05-12 | 2007-03-22 | 브리스톨-마이어스 스큅 컴퍼니 | 혈전 상태의 치료에 유용한 p2y1 수용체의 우레아길항제 |
WO2006014325A2 (en) * | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
US7329652B2 (en) * | 2004-09-17 | 2008-02-12 | Vertex Pharamaceuticals Incorporated | Diaminotriazole compounds useful as protein kinase inhibitors |
EA012181B1 (ru) * | 2004-10-18 | 2009-08-28 | Амген, Инк. | Соединения тиадиазола и их применение |
CA2590294A1 (en) * | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
KR20070100894A (ko) * | 2005-01-19 | 2007-10-12 | 브리스톨-마이어스 스큅 컴퍼니 | 혈전색전성 장애 치료용 p2y1 수용체 억제제로서의2-페녹시-n-(1,3,4-티아디졸-2-일)피리딘-3-아민 유도체및 관련 화합물 |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
NZ563454A (en) | 2005-06-08 | 2011-03-31 | Rigel Pharmaceuticals Inc | 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway |
DE602006020871D1 (de) | 2005-06-27 | 2011-05-05 | Bristol Myers Squibb Co | Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden |
TW200726764A (en) * | 2005-06-27 | 2007-07-16 | Bristol Myers Squibb Co | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
WO2007002634A1 (en) * | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
DE602006017694D1 (de) * | 2005-06-27 | 2010-12-02 | Bristol Myers Squibb Co | C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden |
AU2006299671A1 (en) * | 2005-10-05 | 2007-04-12 | Merck Frosst Canada Ltd | Substituted quinolines as inhibitors of leukotriene biosynthesis |
EP1991532B1 (de) | 2006-02-24 | 2017-01-11 | Rigel Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur hemmung des jak-pfades |
WO2007106391A1 (en) * | 2006-03-10 | 2007-09-20 | Lymphosign Inc. | Compounds for modulating cell proliferation, compositions and methods related thereto |
AU2007303846B2 (en) | 2006-10-04 | 2011-03-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists |
US7960569B2 (en) * | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
WO2008139845A1 (ja) * | 2007-04-24 | 2008-11-20 | Daiichi Sankyo Company, Limited | 新規アミド誘導体 |
MX2010008926A (es) | 2008-02-15 | 2011-02-23 | Rigel Pharmaceuticals Inc | Compuestos de pirimidin-2-amina y su uso como inhibidores de jak cinasas. |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
ES2546502T3 (es) | 2008-04-16 | 2015-09-24 | Portola Pharmaceuticals, Inc. | 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas |
JP2011518219A (ja) | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ, インコーポレイテッド | タンパク質キナーゼの阻害剤 |
CN102099352B (zh) * | 2008-07-10 | 2014-02-26 | 一般社团法人创药分子Ip | 以喹啉甲酰胺衍生物为有效成分的stat3抑制剂 |
KR20110124787A (ko) * | 2009-02-27 | 2011-11-17 | 암비트 바이오사이언시즈 코포레이션 | Jak 키나아제 조절 퀴나졸린 유도체 및 이의 사용 방법 |
US8361962B2 (en) * | 2009-07-27 | 2013-01-29 | Roche Palo Alto Llc | Tricyclic inhibitors of JAK |
PL2520575T3 (pl) * | 2009-12-28 | 2017-05-31 | General Incorporated Association Pharma Valley Project Supporting Organization | Związek 1,3,4-oksadiazolo-2-karboksyamidowy |
KR101483215B1 (ko) * | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
SG186229A1 (en) | 2010-06-07 | 2013-01-30 | Novomedix Llc | Furanyl compounds and the use thereof |
EP2397482A1 (de) * | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroarylimidazolon-Derivate als JAK-Inhibitoren |
CN101891697B (zh) * | 2010-07-02 | 2011-08-31 | 山东大学 | 含1,2,4-噁二唑杂环α,β-不饱和酮类化合物 |
EP2975027A1 (de) | 2010-11-01 | 2016-01-20 | Portola Pharmaceuticals, Inc. | Nicotinamide als jak-kinasemodulatoren |
US9359308B2 (en) | 2011-11-23 | 2016-06-07 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
KR101328126B1 (ko) * | 2012-04-10 | 2013-11-08 | 연세대학교 원주산학협력단 | 신규한 옥사디아졸 유도체 및 이의 알레르기 질환의 예방, 개선 또는 치료적 용도 |
NZ700928A (en) | 2012-04-24 | 2017-06-30 | Vertex Pharma | Dna-pk inhibitors |
CN103382206B (zh) * | 2012-05-04 | 2016-09-28 | 上海恒瑞医药有限公司 | 喹啉或喹唑啉类衍生物、其制备方法及其在医药上的应用 |
WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
WO2014058921A2 (en) | 2012-10-08 | 2014-04-17 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
JP6218848B2 (ja) * | 2012-11-20 | 2017-10-25 | プロキナーゼ ゲゼルシャフト ミット ベシュレンクテル ハフツング | プロテインキナーゼ阻害剤としてのチオエーテル誘導体 |
CL2012003253A1 (es) * | 2012-11-22 | 2013-01-11 | Univ Concepcion | Compuestos derivados de 1,3,4-tiadiazol alquilamidas y de chalconas, antagonistas del receptor trpv-1; uso de los compuestos para tratar el dolor cronico. |
KR102216284B1 (ko) | 2013-03-12 | 2021-02-18 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제 |
HUE041877T2 (hu) | 2013-10-17 | 2019-06-28 | Vertex Pharma | (S)-N-Metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propán-2-il)kinolin-4-karboxamid kokristályai és deuterált származékai DNS-PK inhibitorokként |
US9771333B2 (en) | 2013-11-20 | 2017-09-26 | Signalchem Lifesciences Corp. | Quinazoline derivatives as TAM family kinase inhibitors |
JP6269942B2 (ja) * | 2014-02-20 | 2018-01-31 | 国立研究開発法人理化学研究所 | p38MAPキナーゼγおよび/またはδ阻害剤 |
WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
RU2758669C2 (ru) | 2016-09-27 | 2021-11-01 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк |
US11273154B2 (en) * | 2017-03-03 | 2022-03-15 | Progenra, Inc. | Azole compounds as ubiquitin-specific protease USP7 inhibitors |
CN108148058B (zh) * | 2018-02-08 | 2021-03-16 | 中国人民解放军第四军医大学 | 一种4-(2-巯基噻二唑)取代的嘧啶衍生物其制备方法及应用 |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US20220177978A1 (en) | 2019-04-02 | 2022-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
US20220202820A1 (en) | 2019-04-16 | 2022-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN114380817B (zh) * | 2020-10-21 | 2024-06-21 | 中国医学科学院药物研究所 | 苯并咪唑并2-氨基-1,3,4-噻二唑化合物及其制法和药物用途 |
CN118201924A (zh) * | 2021-11-08 | 2024-06-14 | 万特斯治疗美国公司 | 杂环化合物及其用途 |
WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
WO1999031096A1 (en) * | 1997-12-18 | 1999-06-24 | Shaman Pharmaceuticals, Inc. | Piperazine derivatives useful as hypoglycemic agents |
CA2333770A1 (en) * | 1998-06-04 | 1999-12-09 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
US6486158B1 (en) * | 1998-08-14 | 2002-11-26 | Cell Pathways, Inc. | [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia |
US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
WO2000075145A1 (en) * | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
JP2001354658A (ja) * | 2000-06-15 | 2001-12-25 | Taisho Pharmaceut Co Ltd | ヒドロキシホルムアミジン化合物及びその塩並びにそれらを含む医薬 |
PL360439A1 (en) | 2000-06-28 | 2004-09-06 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
-
2003
- 2003-05-06 AU AU2003299472A patent/AU2003299472A1/en not_active Withdrawn
- 2003-05-06 MX MXPA04011048A patent/MXPA04011048A/es unknown
- 2003-05-06 WO PCT/US2003/014223 patent/WO2004058753A1/en active Application Filing
- 2003-05-06 RU RU2004135386/04A patent/RU2004135386A/ru not_active Application Discontinuation
- 2003-05-06 KR KR10-2004-7017933A patent/KR20050006237A/ko not_active Application Discontinuation
- 2003-05-06 US US10/430,805 patent/US7271179B2/en not_active Expired - Fee Related
- 2003-05-06 EP EP03799762A patent/EP1501829B1/de not_active Expired - Lifetime
- 2003-05-06 AT AT03799762T patent/ATE489384T1/de not_active IP Right Cessation
- 2003-05-06 DE DE60335099T patent/DE60335099D1/de not_active Expired - Lifetime
- 2003-05-06 CA CA002485429A patent/CA2485429A1/en not_active Abandoned
- 2003-05-06 CN CN038159546A patent/CN1665808A/zh active Pending
- 2003-05-06 JP JP2004563181A patent/JP4681302B2/ja not_active Expired - Fee Related
- 2003-05-06 EP EP10182153A patent/EP2316834A1/de not_active Withdrawn
-
2004
- 2004-11-07 IL IL16506704A patent/IL165067A0/xx unknown
- 2004-12-02 NO NO20045282A patent/NO20045282L/no not_active Application Discontinuation
-
2010
- 2010-04-26 JP JP2010101525A patent/JP2010159306A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN1665808A (zh) | 2005-09-07 |
WO2004058753A8 (en) | 2005-06-16 |
AU2003299472A1 (en) | 2004-07-22 |
JP2006513192A (ja) | 2006-04-20 |
KR20050006237A (ko) | 2005-01-15 |
EP2316834A1 (de) | 2011-05-04 |
JP2010159306A (ja) | 2010-07-22 |
US7271179B2 (en) | 2007-09-18 |
EP1501829A1 (de) | 2005-02-02 |
JP4681302B2 (ja) | 2011-05-11 |
EP1501829B1 (de) | 2010-11-24 |
WO2004058753A1 (en) | 2004-07-15 |
ATE489384T1 (de) | 2010-12-15 |
MXPA04011048A (es) | 2005-02-17 |
US20040038992A1 (en) | 2004-02-26 |
CA2485429A1 (en) | 2004-07-15 |
NO20045282L (no) | 2005-02-07 |
IL165067A0 (en) | 2005-12-18 |
RU2004135386A (ru) | 2005-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60335099D1 (de) | Thiadiazole oder oxadiazole und ihre verwendung als jak proteinkinaseinhibitoren | |
EA200600351A1 (ru) | Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортёра | |
ATE334975T1 (de) | Sulfonamidderivate, ihre herstellung und verwendung | |
NO953305L (no) | Antranilsyrederivat | |
AR017236A1 (es) | Compuestos biciclo [2.2.1] heptanos, composiciones farmaceuticas, procedimientos para tratar | |
ES2196396T3 (es) | Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa. | |
ATE247654T1 (de) | Neue heterozyklische verbindungen | |
DK1277736T3 (da) | Hidtil ukendte bicykliske forbindelser | |
CY1107509T1 (el) | Αμινοθειαζολες ως αναστολεις κυκλινη - εξαρτωμενων κινασεων | |
DE60314639D1 (de) | Fusionierte heteroaryl-derivative zur verwendung als p38 kinase inhibitoren zur behandlung von u.a rheumatischer arthritis | |
DE60017115D1 (de) | Amid-derivate und deren medizinische verwendung | |
ATE385238T1 (de) | Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände | |
ATE541833T1 (de) | Stickstoff-enthaltende verbindungen mit kinasehemmender wirkung sowie diese enthaltende medikamente | |
DE69709532T2 (de) | 1-Phenyl-Pyrazolderivate und ihr Verwendung als Schädlingsbekämpfungsmittel | |
LV12047A (lv) | Kondenseti pirimidina atvasinajumi un to lietosana par angiotenzina II antagonistiem | |
PT1202957E (pt) | Aminobenzofenonas como inibidoras de il-1beta e tnf-alpha | |
ATE491704T1 (de) | 4-ä2-(cycloalkylamino)pyrimidin-4-ylü- (phenyl)imidazolin-2-onderivate als inhibitoren der p38-map-kinase zur behandlung von entzündlichen krankheiten | |
HUP0000189A2 (hu) | Biciklusos aril-karboxamid-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk terápiás célokra | |
ATE324890T1 (de) | Zusammensetzung enthaltend einen angiotensin-ii- rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck | |
ATE185800T1 (de) | 1-aminoacetamidopyrrole und 1-amino-2- (substituierte)-pyrrole und ihre verwendung zur behandlung von neurodegenerativen störungen | |
JP2004512281A5 (de) | ||
PT98747A (pt) | Processo para a preparacao de 6,7-dihidro-3-fenil-1-1,2-benzisoxazol-4(5h)-onase -ois e de composicoes farmaceuticas que os contem | |
DE68904342D1 (de) | Cyclische amide. | |
ATE208761T1 (de) | Quinolin-derivate und diese enthaltende pharmazeutische zusammensetzungen | |
ATE142201T1 (de) | 2- und 3-amino und azidoderivate von 1,5- iminozuckern als antivirale arzneimittel |